B7H3-IRDye800CW (Simcere Pharma)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameB7H3-IRDye800CW (Simcere Pharma)
Drug Alias NameIRDye800CW-B7H3 antibody (Simcere Pharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsMargins of ExcisionOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMargins of ExcisionOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A